Clinical Trial Update: Sorafenib and Bortezomib in Treating Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study to evaluate the combination of sorafenib and bortezomib in patients with advanced cancers, including refractory chronic lymphocytic leukemia and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Multiple Myeloma

Drugs mentioned

• Nexavar (Sorafenib)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED